Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients?

被引:15
作者
Bainey, K. R.
Fu, Y.
Granger, C. B. [2 ]
Hamm, C. W. [3 ]
Holmes, D. R., Jr. [4 ]
O'Neill, W. W. [5 ]
Seabra-Gomes, R. [6 ]
Pfisterer, M. E. [7 ]
Van de Werf, F. [8 ]
Armstrong, P. W. [1 ]
机构
[1] Univ Alberta, Div Cardiol, Edmonton, AB T6G 2H7, Canada
[2] Duke Clin Res Inst, Durham, NC USA
[3] Kerckhoff Heart Ctr, Bad Nauheim, Germany
[4] Mayo Clin, Rochester, MN USA
[5] Univ Miami, Miami, FL USA
[6] Inst Coracao, Lisbon, Portugal
[7] Univ Basel Hosp, CH-4031 Basel, Switzerland
[8] Univ Hosp Gasthuisberg, B-3000 Leuven, Belgium
关键词
ACUTE MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY ANGIOPLASTY; PLATELET-FUNCTION; BLOOD-GLUCOSE; MELLITUS; THERAPY; HYPERGLYCEMIA; DISEASE; IMPACT;
D O I
10.1136/hrt.2008.160390
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: Spontaneous reperfusion (SR) in ST elevation myocardial infarction (STEMI) improves clinical outcome, yet its incidence and impact among diabetic patients is unclear. Objective: To carry out a systematic analysis of SR in the diabetic cohort of a large primary percutaneous coronary intervention (PCI)-treated population with STEMI. Methods and results: 4944 patients (15.5% diabetic) undergoing primary PCI in the APEX AMI study were evaluated. SR defined as pre-PCI Thrombolysis in Myocardial Infarction (TIMI) 3 flow occurred in 11.5% of patients; it was more common in non-diabetic (11.9%) than in diabetic patients (9.2%) (p = 0.028). Patients with SR versus no SR had improved post-PCI TIMI 3 flow: in non-diabetic patients (99.8% vs 90.3%, p<0.001) and in diabetic patients (98.6% vs 84.9%, p<0.001). Non-diabetic patients with SR showed a significant improvement in 90-day death/shock/congestive heart failure (CHF) compared with those without SR: 4.4% versus 8.9% (p = 0.001), respectively. The composite outcome in diabetic patients with versus without SR was 10.0% versus 14.9% (p = 0.270), respectively. When outcomes were examined according to tertiles of baseline blood glucose, both non-diabetic and diabetic patients with normoglycaemia showed higher SR rates (15.5%, 10.3%, 7.3% for non-diabetic patients, p<0.001; 17.4%, 7.2%, 9.1% for diabetic patients, p = 0.132), greater ST resolution (55.4%, 52.6%, 49.7% for non-diabetic patients, p = 0.030; 50%, 46.4%, 39.1% for diabetic patients, p = 0.179), and improved 90-day death/shock/CHF (5.2%, 8.3%, 14% for non-diabetic patients p < 0.001; 8.7%, 4.2%, 15.8% for diabetic patients, p = 0.006). Conclusions: These data indicate that SR is less common in diabetic patients with STEMI. Diabetic patients without SR have worse post-PCI epicardial patency, which contributes to adverse outcomes. Diabetic patients with normal baseline blood glucose and SR have enhanced epicardial flow after PCI and improved prognosis.
引用
收藏
页码:1331 / 1336
页数:6
相关论文
共 28 条
[1]
Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy [J].
Angeja, BG ;
de Lemos, J ;
Murphy, SA ;
Marble, SJ ;
Antman, EM ;
Cannon, CP ;
Braunwald, E ;
Gibson, CM .
AMERICAN HEART JOURNAL, 2002, 144 (04) :649-656
[2]
Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43
[3]
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [J].
Armstrong, PW ;
Adams, PX ;
Al-Khalidi, HR ;
Hamm, C ;
Holmes, D ;
O'Neill, W ;
Todaro, TG ;
Vahanian, A ;
Van de Werf, F ;
Granger, CB .
AMERICAN HEART JOURNAL, 2005, 149 (03) :402-407
[4]
Atherothrombosis, inflammation, and diabetes [J].
Biondi-Zoccai, GGL ;
Abbate, A ;
Liuzzo, G ;
Biasucci, LM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (07) :1071-1077
[5]
Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus [J].
Calverley, DC ;
Hacker, MR ;
Loda, KA ;
Brass, E ;
Buchanan, TA ;
Tsao-Wei, DD ;
Groshen, S .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (01) :139-142
[6]
Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview [J].
Capes, SE ;
Hunt, D ;
Malmberg, K ;
Gerstein, HC .
LANCET, 2000, 355 (9206) :773-778
[7]
Diabetes and vascular disease -: Pathophysiology, clinical consequences, and medical therapy:: Part I [J].
Creager, MA ;
Lüscher, TF ;
Cosentino, F ;
Beckman, JA .
CIRCULATION, 2003, 108 (12) :1527-1532
[8]
THROMBOXANE BIOSYNTHESIS AND PLATELET-FUNCTION IN TYPE-II DIABETES-MELLITUS [J].
DAVI, G ;
CATALANO, I ;
AVERNA, M ;
NOTARBARTOLO, A ;
STRANO, A ;
CIABATTONI, G ;
PATRONO, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (25) :1769-1774
[9]
PLASMINOGEN-ACTIVATOR INHIBITOR ACTIVITY IN DIABETIC AND NONDIABETIC SURVIVORS OF MYOCARDIAL-INFARCTION [J].
GRAY, RP ;
PATTERSON, DLH ;
YUDKIN, JS .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (03) :415-420
[10]
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [J].
Haffner, SM ;
Lehto, S ;
Rönnemaa, T ;
Pyörälä, K ;
Laakso, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) :229-234